179 related articles for article (PubMed ID: 22672147)
1. Allergenic vaccines administration and inhibitor development in haemophilia.
Bermejo N; Martín Aguilera C; Carnicero F; Bergua J
Haemophilia; 2012 Sep; 18(5):e392-3. PubMed ID: 22672147
[No Abstract] [Full Text] [Related]
2. Late immune tolerance induction in an adult with severe haemophilia A and high-responder inhibitor: 1-year outcome.
Faradji A; Lavigne-Lissalde G; Grunebaum L; Desprez D; Feugeas O; Lapalud P
Haemophilia; 2012 Sep; 18(5):e388-91. PubMed ID: 22765638
[No Abstract] [Full Text] [Related]
3. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
[TBL] [Abstract][Full Text] [Related]
4. Successful eradication of inhibitor of late recurrence and other high risk prognostic factors in a patient with severe haemophilia A.
Ranta S; Koskinen S; Mäkipernaa A
Haemophilia; 2011 Sep; 17(5):e833-4. PubMed ID: 21624011
[No Abstract] [Full Text] [Related]
5. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
Pinto P; Ghosh K; Shetty S
Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
[TBL] [Abstract][Full Text] [Related]
6. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
[No Abstract] [Full Text] [Related]
7. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.
Mannucci PM; Abshire T; Dimichele D; Santagostino E; Blanchette V
Haemophilia; 2006 Jul; 12(4):429-34. PubMed ID: 16834746
[No Abstract] [Full Text] [Related]
8. A case report of a premature infant with haemophilia A and factor VIII inhibitor.
Cartledge P; Deakin K; McKecknie L; Richards M
Haemophilia; 2011 Jul; 17(4):711-2. PubMed ID: 21371187
[No Abstract] [Full Text] [Related]
9. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
[No Abstract] [Full Text] [Related]
10. A child with acquired haemophilia.
Somaratne PD; Jansan J; Senanayake HM; Ratnamalala V; Jayathilake MM; Thirumavalavan K
Ceylon Med J; 2014 Jun; 59(2):66-7. PubMed ID: 24977427
[No Abstract] [Full Text] [Related]
11. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
[No Abstract] [Full Text] [Related]
13. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
Wu RH; Wei QQ
Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
[No Abstract] [Full Text] [Related]
14. Rehabilitation improved walking ability for three haemophilia patients with inhibitors.
Shimokawa A; Takedani H
Haemophilia; 2014 May; 20(3):e222-4. PubMed ID: 24589064
[No Abstract] [Full Text] [Related]
15. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required.
Calvez T; Laurian Y
Br J Haematol; 2006 Mar; 132(6):798-800; author reply 800-1. PubMed ID: 16487187
[No Abstract] [Full Text] [Related]
17. Successful response to rituximab in two cases of acquired haemophilia refractory to standard-therapy.
Machado P; Raya JM; Martín T; Morabito L; Brito ML; Rodríguez-Martín JM
Int J Hematol; 2008 Jun; 87(5):545-549. PubMed ID: 18414981
[TBL] [Abstract][Full Text] [Related]
18. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
19. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
